1. Mechanisms of Acute Myocardial Infarction --;2. New Generation Thrombolytic Agents --;3. Antiplatelet Agents --;4. Thrombin Inhibitors --;5. The Thrombolysis in Myocardial Infarction (TIMI) Trials --;6. The Clinical Trials of the European Cooperative Study for Recombinant Tissue-Type Plasminogen Activator (rt-PA) --;7. The International Studies of Infarct Survival (ISIS) --;8. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trials --;9. Trial of Prehospital Thrombolysis for Acute Myocardial Infarction: Is Sooner Necessarily Better? --;10. The Late Assessment of Thrombolytic Efficacy (LATE) Trial: Impact and Implications --;11. The Global Utilization of t-PA and Streptokinase for Occluded Coronary Arteries (GUSTO-I) Trial --;12. The Management of Heart Failure in the Age of Reperfusion --;13. Thrombolytic Therapy in Elderly Patients --;14. Thrombolytic Retreatment for Coronary Arterial Reocclusion --;15. Radionuclide Imaging Techniques in the Thrombolytic Era --;16. Biochemical Markers of Coronary Recanalization after Fibrinolytic Therapy --;17. Monitoring Anticoagulant Therapy in the Setting of Thrombolytic Therapy --;18. Acute Coronary Syndromes: Focus on Unstable Angina --;19. Future of Coronary Thrombolysis.
SUMMARY OR ABSTRACT
Text of Note
Thrombolytic therapy has revolutionized the treatment of myocardial infarction, saving lives to a greater extent than any treatment developed to date. The emergence of information vital for patient care has appeared at an extraordinary pace, with hundreds of articles being published yearly.